期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新辅助化疗对局部晚期乳腺癌中ER、PR、C-erbB-2表达的影响 被引量：2

Influence of Neoadiuvant Chemotherapy on the Expression of ER、PR、C-erbB-2 In Patients with Locally Advanced Breast Cancer
在线阅读 下载PDF
导出
摘要 目的探讨新辅助化疗对局部晚期乳腺癌中ER、PR及C-erbB-2的表达有无影响。方法通过免疫组化的方法检测新辅助化疗前粗针穿刺标本及术后标本的ER、PR及C-erbB-2的表达情况。结果新辅助化疗前后ER、PR及C-erb-2表达状态发生改变的分别有5例、10例及7例。新辅助化疗前后ER、PR及C-erbB-2的表达无显著性差异(P>0.05)。结论新辅助化疗可使部分晚期乳腺癌患者的EP、PR及C-erbB-2的表达发生变化,但EP、PR及C-erbB-2的表达变化无统计学意义,说明新辅助化疗不会影响晚期乳腺癌患者的ER、PR及C-erbB-2的表达。 Objective To explore neoadjuvant chemotherapy locally advanced breast cancer to ER, PR and C-erb-2 without the express impact. Methods Through the immunohistochemical determination of the new adjuvant chemotherapy before thick needle biopsy specimens were Collected and postoperative ER, PR and C-erbB-2 expression. Results ER, Pr and C-erbB -2 expression before and after chemotherapy state changes respectively in 5 cases, 10 cases and 7 cases. Statistical analysis results show that that the new adjuvant chemotherapy ER, PR and C-erbB -2 before and after express no significant differences （ P〉0.05 ）. Conclusion Neoadjuvant chemotherapy with advanc6d breast cancer can be made part of the EP, PR and C-erbB-2 expression changes, but EP, PR and C-erbB- 2 expression change was not statistically significant.Neoadjuvant chemotherapy with advanced breast cancer does not affect the ER, PR and C-erbB-2 expression.
作者 田萌子 毕研青
机构地区 东营市人民医院普外科
出处 《中国现代医生》 2011年第23期62-64,共3页 China Modern Doctor
关键词 新辅助化疗 局部晚期乳腺癌 ER PR C—erbB-2 免疫组织化学 Neoadjuvant chemotherapy Locally advanced breast cancer ER PR C-erbB-2 Immunohistoehemical
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Ranieri G, Patruno R, Ruggieri E, et al.Vascular endothelial growth factor ( VEGF ) as a target of bevacizumab in cancer: from the biology to the clinic[J]. Curr Medchem,2006,13 ( 16): 1845-1857.
  • 2Bear HD, Andensen S, Brown A, et al. The effect on tumor response of adding sequential preopretive docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuent Breast and Bowol Project Protocol B-27[J]. Clin Oncol,2003,21 : 4165-4174.
  • 3Bardou V J, Arpino G, Elledge RM, et al. Progesterone receptors status significantly improves outcome prdcdiction over estrogen receptor status alone for aduvent endocrinetherapy in two large breast cancer databases[J]. J Clin Oncol,2003,21 ( 10): 1973-1979.
  • 4Hamilton A, Piccart M, The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2[J]. Ann Oncol,2000,11 ( 6 ) : 647-663.
  • 5CristafanilliM, C.onzalez-AnguloA, SneigeN, etal. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes[J]. J Clin Oneol,2005,23 ( 1 ) : 41-48.
  • 6PrisackHB, KarrernanC, Modlieho, etal. Predietive biological markers for respome of invasive breast cancer to anthracycline/cyclophosphandde-based primary( radio- ) chemotherapy[J]. Antieancer Res,2005,25 ( 6C ): 4615-4621.
  • 7Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preperative treatment[l]. Clin Cancer Bes, 2004,10 ( 19 ) : 6622-6628.
  • 8费伯健,周士福,金留根,林奇.新辅助化疗对乳腺癌激素受体表达和状态的影响[J].南京医科大学学报（自然科学版）,2005,25(11):772-774. 被引量：18

二级参考文献9

  • 1Fromowitz FB, Viola MV, Chao S, et al. Ras p21expression in the progression of breast cancer [J]. Hum Pathol, 1987,18:1268-1273.
  • 2Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. Clin Oncol,2003,21:4165-4174.
  • 3Buchholz TA, Stivers DN, Stec J. et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer [ J ]. Cancer J, 2002,8: 461-468.
  • 4Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma[J]. Am Surg, 1996,62:162-165.
  • 5Makris A, Powles TJ, Allred DC, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study [J].Breast Cancer Res Treat, 1999,53: 51-59.
  • 6Schneider J, Lucas R, Sanchez J, et al. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDRI and LRP [ J ]. Anticancer Res, 2000,20:4373-4377.
  • 7Lee SH, Chung MA, Quddus MR. The effect of neoadjuvantchemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer[J]. Am J Surg,2003,186:348-350.
  • 8Piper GL, Patel NA, Malay MB, et al. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status [J]. Am J Surg,2004,70:1103-1106.
  • 9Fisher ER, Wang J, Bryant J, el al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-18 [J].Cancer, 2002,95 : 681-695.

共引文献17

同被引文献10

引证文献2

二级引证文献13

中国现代医生
2011年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部